Griseofulvin, A Novel Host-directed Antimalarial Drug
Funder
National Health and Medical Research Council
Funding Amount
$461,551.00
Summary
This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.
Targeting An Ion Pump In The Malaria Parasite With Multiple Compound Classes
Funder
National Health and Medical Research Council
Funding Amount
$384,686.00
Summary
Large-scale antimalarial drug screening projects have identified three different classes of compound that kill the malaria parasite at extremely low doses and which hold real promise as next-generation antimalarials. Genetic evidence, as well as preliminary data from our own lab, has led us to the hypothesis that all three compound classes exert their antimalarial effect by blocking a molecular ion pump on the parasite surface. The aim of this study is to test this.
Identification of structural proteins in the tissue cyst wall of Toxoplasma gondii. Most infections with Toxoplasma gondii are asymptomatic, however, infection during pregnancy can lead to miscarriage or blindness, deafness and mental retardation in the developing baby. Furthermore, in AIDS patients, toxoplasmosis is the leading cause of fatal encephalitis as the normally dormant tissue cysts are reactivated in the absence of an effective immune system. In Australia, it has been estimated that ~ ....Identification of structural proteins in the tissue cyst wall of Toxoplasma gondii. Most infections with Toxoplasma gondii are asymptomatic, however, infection during pregnancy can lead to miscarriage or blindness, deafness and mental retardation in the developing baby. Furthermore, in AIDS patients, toxoplasmosis is the leading cause of fatal encephalitis as the normally dormant tissue cysts are reactivated in the absence of an effective immune system. In Australia, it has been estimated that ~30% of the population is infected with T. gondii and the occurrence of congenital toxoplasmosis is 0.2% of live births, which translates to roughly 500 cases/year. Our research will identify structural proteins in Toxoplasma cyst walls that will lead to the design of new strategies to control the diseases caused by these parasites.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE120101529
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Transmission dynamics modelling of zoonotic neglected tropical diseases. This project will develop mathematical models to simulate zoonotic disease transmission and control. Results will provide novel insight for policy makers into effective interventions for schistosomiasis, echinococcosis and clonorchiasis, as well as provide a methodological platform for adaptation to other zoonotic emerging and re-emerging diseases.
A novel approach for controlling insect vectors of human disease. Insects are responsible for transmitting a wide variety of debilitating human diseases such as malaria, dengue and yellow fever. Unfortunately, there are very few options available for controlling these insect pests. This project will develop a novel, eco-friendly approach for control of mosquitoes and other important disease vectors.